Skip to main content
Healthcare

Healthcare ESG: Drug Access, Innovation Ethics, and Social Considerations

Pomegra Learn

What ESG Considerations Apply to Healthcare Investing?

Healthcare ESG analysis focuses on different issues than most other sectors because the sector's products and services directly affect human health and survival. Drug pricing and access — whether life-saving medications are available to patients who need them regardless of income — is the most contentious healthcare ESG issue. Clinical trial ethics, environmental sustainability of healthcare operations, data privacy for health information, and the labor practices of healthcare service organizations complete the ESG landscape for the sector. Understanding how these issues affect investor expectations, regulatory risk, reputational exposure, and potentially long-term business sustainability helps investors integrate ESG factors alongside fundamental financial analysis.

Quick definition: Healthcare ESG analysis centers on drug pricing and access (the ability of patients worldwide to afford essential medicines), clinical trial ethics (fair participant selection, informed consent, post-trial access), environmental sustainability (pharmaceutical manufacturing's chemical footprint, medical waste), patient data privacy, and healthcare workforce labor practices — with drug pricing being the most financially material ESG issue affecting pharmaceutical company valuations.

Key takeaways​

  • Drug pricing and access is the most financially significant healthcare ESG issue — congressional investigations, media scrutiny, and IRA drug price negotiation all reflect the political materiality of this concern
  • Insulin pricing controversy — with US insulin prices historically 10x above other developed countries — demonstrates how access-related controversies can generate regulatory action with direct financial impact
  • Pharmaceutical companies face ESG scrutiny for "evergreening" — filing additional patents to extend exclusivity beyond initial protection and delaying generic competition
  • Emerging market access — making essential medicines available in low-income countries — is a governance and reputational issue for global pharmaceutical companies
  • Healthcare data privacy (HIPAA compliance, data breach risk) is increasingly material as digital health and EHR data become more valuable and more vulnerable to cybersecurity threats

Drug pricing and access​

The US pricing paradox: The United States pays substantially higher drug prices than other developed countries — US drug prices are typically 2–5x prices in the EU, UK, Canada, or Japan for the same products. This pricing differential reflects the US system's historical prohibition on Medicare price negotiation, market-based pricing freedom, and pharmaceutical companies' ability to charge what the market will bear without direct government intervention.

Access implications: High US drug prices create access barriers for uninsured and underinsured Americans. Insulin (a century-old drug essential for Type 1 diabetics) became a symbol of access failures — US insulin list prices reached $300–400 per vial versus $20–30 in Canada for identical products. Congressional and public pressure resulted in insulin price caps for Medicare and insulin manufacturer commitments to $35/month caps.

Evergreening controversy: Pharmaceutical companies extend patent protection through "evergreening" — filing new patents on reformulated versions (extended-release formulations, new combinations), alternative dosing schedules, or secondary uses that delay generic competition beyond the original patent. While legally permissible, evergreening is criticized as prioritizing revenue extraction over patient access. Humira (adalimumab) had over 100 patents filed — delaying substantial biosimilar competition for years beyond the original biologic patent.

Access programs: Major pharmaceutical companies operate patient assistance programs (PAP) providing free or reduced-cost drugs to qualifying low-income patients. These programs reduce access-related reputational risk but are administratively complex and provide incomplete coverage. ESG frameworks assess the breadth and accessibility of these programs.

Clinical trial ethics​

Historic trial ethics failures: Tuskegee Syphilis Study (1932–1972, US government failure to treat Black men with syphilis to observe disease progression), Guatemalan syphilis experiments (1946–1948, deliberate infection without consent), and offshore clinical trials with inadequate informed consent have shaped the ethical framework governing modern clinical research.

Informed consent requirements: The Declaration of Helsinki and FDA regulations require meaningful informed consent from trial participants — understanding risks, benefits, alternatives, and rights. ESG evaluation includes whether companies conduct trials in populations with limited ability to provide free and meaningful consent (prisoners, terminally ill patients, populations in low-income countries with inadequate healthcare alternatives).

Diversity in clinical trials: FDA has increased requirements for diverse clinical trial enrollment — requiring enrollment reflecting the demographic diversity of patients who will use the drug. Trials that enroll primarily white, male, or older populations may not adequately represent how drugs will perform in women, racial minorities, or younger patients. Lack of diverse enrollment is both an ethical concern and a scientific limitation.

Post-trial access: Participants in clinical trials in developing countries who benefit from experimental drugs face the question of whether they will have access to those drugs if approved — particularly for drugs priced beyond the means of most patients in their countries. ESG frameworks evaluate whether companies have commitments to post-trial access for trial participants.

How it flows​

Environmental sustainability in Healthcare​

Pharmaceutical manufacturing environmental footprint: Drug manufacturing generates chemical waste, solvents, and process water contamination. Pharmaceutical compounds in waterways (from manufacturing discharge and patient excretion) represent an emerging environmental issue — some antibiotics, hormones, and psychiatric drugs are detectable in waterways globally, with potential ecological effects.

Energy intensity: Pharmaceutical and life sciences manufacturing is energy-intensive — large fermentation operations (biologics), controlled temperature storage, and laboratory energy consumption make the sector a meaningful energy consumer. Companies have set emissions reduction targets (net-zero by 2040–2050) but progress requires substantial facility investment.

Medical waste: Hospital and clinical healthcare operations generate large volumes of medical waste — sharps, contaminated materials, pharmaceutical waste — requiring regulated disposal. Environmental management of medical waste is primarily a healthcare facility compliance cost rather than a pharmaceutical company issue.

Green chemistry: The pharmaceutical industry is investing in "green chemistry" — drug synthesis processes that reduce solvent use, eliminate hazardous intermediates, and improve energy efficiency. Pfizer, AstraZeneca, and Novartis have published green chemistry commitments with specific metric targets.

Patient data privacy and cybersecurity​

HIPAA framework: The Health Insurance Portability and Accountability Act (HIPAA) requires healthcare companies to protect protected health information (PHI) through administrative, physical, and technical safeguards. HIPAA violations can result in substantial penalties — up to $1.9 million per violation category per year.

Healthcare data value and vulnerability: Electronic health records (EHRs), claims data, and genomic data are increasingly valuable — to healthcare companies, researchers, and unfortunately to cybercriminals. Healthcare organizations have been significant targets for ransomware attacks because healthcare data is valuable and healthcare organizations often have older IT infrastructure.

Change Healthcare cyberattack (2024): UnitedHealth Group's Change Healthcare subsidiary suffered a major ransomware attack in 2024 that disrupted payment processing for billions of healthcare transactions — a real-world illustration of healthcare cybersecurity risk with substantial financial impact. UnitedHealth incurred approximately $1 billion+ in direct costs from the attack.

Genomic data privacy: Direct-to-consumer genomic testing companies (23andMe, AncestryDNA) and healthcare companies using genomic data face unique privacy challenges — genetic information is immutable (cannot be changed if breached), can reveal information about family members who haven't consented to disclosure, and carries potential insurance and employment discrimination risks despite legal protections.

Labor practices in healthcare services​

Healthcare workforce shortage: The US faces significant nursing, physician, and allied health professional shortages — a structural challenge that creates labor cost inflation for healthcare facilities and service providers. Hospital systems face nursing strike actions, travel nurse premium costs (2–3x regular nurse compensation), and ongoing retention challenges.

Wages and working conditions: Healthcare workers (particularly nurses, CNAs, and support staff) often work demanding schedules with inadequate staffing ratios. ESG frameworks evaluate whether healthcare companies invest in workforce development, pay equitable wages, and maintain safe working conditions. The pandemic-driven healthcare workforce burnout wave significantly worsened staff turnover.

Geographic access to care: Healthcare ESG also considers whether healthcare companies serve underserved communities — rural areas, urban low-income neighborhoods — or concentrate services in wealthy markets with better reimbursement. ESG-conscious investors evaluate whether healthcare companies have community benefit programs and whether their service footprint addresses access disparities.

ESG impact on pharmaceutical valuations​

Access controversy valuation discount: Companies facing severe access criticism (Martin Shkreli's Daraprim price increase, Mylan's EpiPen pricing controversy) can face regulatory action, Congressional testimony requirements, and reputational damage that creates valuation discounts. Political attention on drug pricing has been a persistent overhang on pharmaceutical sector valuations.

ESG inclusion/exclusion in pharmaceutical: Unlike tobacco (near-universally excluded from ESG funds), pharmaceutical companies are generally included in ESG portfolios with different ratings based on their access programs, clinical trial practices, environmental footprint, and governance. MSCI, Sustainalytics, and other ESG rating providers assess pharmaceutical companies on healthcare-specific criteria.

IRA connection: The Inflation Reduction Act's drug price negotiation authority was partially driven by ESG-type access concerns — the political argument that Medicare should have power to reduce drug prices to improve affordability. ESG concerns materialized into regulatory action.

Common mistakes​

Treating drug pricing controversy as purely political with no financial impact. The IRA demonstrates that drug pricing ESG issues can materialize into concrete regulatory action with direct financial implications. Companies with the most extreme pricing practices face the greatest regulatory risk — Insulet, Lilly, and Amgen all faced Congressional scrutiny before or alongside regulatory changes.

Underweighting cybersecurity risk in healthcare company analysis. The Change Healthcare attack illustrated that healthcare cybersecurity risk is not theoretical — it can cause billion-dollar operational and financial impacts. Evaluating healthcare company IT security investment and business continuity planning is a legitimate component of investment risk analysis.

FAQ​

How can investors assess pharmaceutical companies' drug access ESG performance?​

Access To Medicine Foundation (accesstomedicine.org) publishes biennial rankings of pharmaceutical companies' access practices in low-income countries. MSCI ESG Ratings and Sustainalytics provide sector-specific ESG scores for individual healthcare companies. Companies' own sustainability reports disclose patient assistance program statistics, generic licensing agreements, and access commitment metrics.

Summary​

Healthcare ESG analysis centers on drug pricing and access (the most financially material healthcare ESG issue, having contributed to the IRA drug pricing legislation), clinical trial ethics (informed consent, diversity, post-trial access), pharmaceutical environmental footprint (chemical waste, energy intensity, green chemistry), and patient data privacy (HIPAA compliance, cybersecurity risk). Drug pricing controversy — particularly the US pricing premium relative to other countries — has created ongoing political and regulatory risk that has materially affected pharmaceutical company valuations through the IRA and insulin price cap legislation. Cybersecurity risk in healthcare has moved from theoretical to real-world financial impact with the Change Healthcare ransomware attack. ESG-conscious investors can assess pharmaceutical access practices through Access To Medicine Foundation rankings and third-party ESG rating services. Unlike tobacco (excluded from most ESG portfolios), pharmaceutical companies are generally included in ESG funds with access-adjusted ratings that create performance differentials based on company-specific access practices.

Next​

→ Healthcare Earnings: Reading Reports and Key Metrics